News | February 19, 2022
Natco Q3FY22 PAT up 27% to Rs 80 Cr
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
The newly enhanced drug development platform will help empower innovators with the fastest development timelines
Moderna's vaccine has already received regulatory approval for adults and adolescents in Australia
Resolv ER may remedy leading causes of blindness in adults
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
Apexxnar is the first pneumococcal conjugate vaccine to help protect adults ages 18 years and older against 20 serotypes responsible for the majority of invasive disease and pneumococcal pneumonia
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
The entire integration and transition of the brands is expected to be completed by March 2022
Key takeaways of Q3FY22 quarter & conference call highlights
Bebtelovimab neutralizes Omicron as demonstrated by pseudo virus and authentic virus data
Subscribe To Our Newsletter & Stay Updated
